The original poster saw glucose jump into the high 200s the day after beginning a stack that includes tesamorelin and reta, despite prior research suggesting no impact. Several replies point to tesamorelin's growth-hormone effects as a likely driver of insulin resistance, while others stress that adding many compounds at once without baselines makes causation impossible to isolate. The discussion reveals the poster is type 1, prompting warnings against GLP-1 agents like reta without specialist oversight and calls to stop or test one variable at a time.
What this discussion establishesWhether tesamorelin or reta is more likely responsible for the observed spike
Still openThe exact cause and whether dose reduction would resolve it without further testing
Nothing here is advice.
I began using this combination of substances just a day ago. According to everything I looked into beforehand, these particular compounds shouldn't influence my glucose readings at all. Despite that, they've been sitting in the upper two hundreds throughout the entire day so far, which doesn't match my typical range of about seventy to one hundred fifty. The substances consist of reta, ghk-cu, bpc157 combined with tb, five amino one q, mots c, aod9604, and tesamorelin. Has anyone noticed their blood glucose increasing from one of these, and if so which, plus whether the effect faded away or required halting the intake?
One possibility is that tesamorelin can increase glucose through growth-hormone-driven insulin resistance, even if most of the others should not. The jump from the 70-150 range into the 200s is substantial. Had you obtained any baseline numbers such as fasting glucose, insulin, or IGF-1 before beginning? It could be useful to remove one item, particularly tesamorelin, and check whether readings return to normal.
That could well be the cause. I might try cutting the dose in half first and observe the outcome rather than stopping right away. Still, if it truly produces insulin resistance I would not continue. Appreciate the input.
To help everyone understand better you would need to share your body measurements, A1C status, diet, and similar details.
Following along, since I have long wondered whether some people using tesamorelin end up needing reta or metformin the way high-dose HGH users sometimes do.
Your choice, but if IGF-1 is already high then adding tesamorelin can further stimulate that pathway and raise the chance of glucose problems. Readings in the 200s are not an ideal setting for testing dose changes. Without prior lab work I would probably pause, allow levels to settle, and then recheck with proper tests before considering whether to continue.
That is a large number of substances introduced together, and baseline labs would be important to track changes, especially anything related to growth hormone but also a general metabolic panel. Starting with smaller amounts makes sense because the combined effects are unknown.
A single dose of tesamorelin seems unlikely to be responsible. Glucose changes from growth hormone usually require longer use, and the pulse from tesamorelin is milder. Over time reta should actually help offset any glucose impact from growth hormone or secretagogues. Something else may be occurring.
While using reta my fasting glucose has remained around 110-120, whereas it had been below 110 beforehand.
In an earlier thread the original poster mentioned being type 1.
Tesamorelin does not work for me. Even years-younger growth hormone raised my glucose and A1C. After three weeks on tesamorelin my glucose reached 130 and A1C hit 6. Once I stopped, glucose stayed at 100-105. I have been borderline prediabetic for the last five years, so I will no longer use tesamorelin or any growth-hormone secretagogue.
I was trying to understand how readings could reach definite diabetes territory above 200. Use of GLP-1 agents in type 1 diabetes remains far from standard practice, though some studies suggest possible benefit with acceptable safety. Adding many new peptides simultaneously makes it difficult to determine which one is responsible for any side effect, and with type 1 diabetes extra caution is warranted by introducing them singly with close monitoring. No studies on reta in type 1 appear to exist, and because it includes glucagon its behavior could differ in low-insulin states compared with type 2 or obesity settings. The high readings could therefore stem from reta or from another factor.
I missed that detail earlier. I would not experiment with any GLP-1 compounds, particularly reta, without close supervision from an endocrinologist who understands the situation.
You began the entire combination on the same day rather than adding one item at a time? That leaves no way to tell what is doing what. This is not a competition to use the most compounds. Health outcomes matter more, so proceed accordingly. As a type 1 patient I would not continue without direct physician oversight rather than telehealth.
If you have tried it, this topic is still open. Sign in to reply — it takes a minute.